Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -29.37% | -5.39% | -1.77% | 6.66% | 16.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.37% | -5.39% | -1.77% | 6.66% | 16.02% |
| Cost of Revenue | 12.93% | -14.73% | -12.05% | -4.57% | -6.62% |
| Gross Profit | -17.05% | -34.36% | -30.54% | -23.54% | -11.98% |
| SG&A Expenses | -9.59% | -28.07% | -21.57% | -4.07% | -14.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.75% | -0.88% | 6.13% | 21.97% | 13.48% |
| Operating Income | -56.72% | -28.20% | -30.81% | -46.38% | 30.21% |
| Income Before Tax | -208.05% | -183.95% | -169.77% | -75.05% | -75.03% |
| Income Tax Expenses | -42.61% | 243.37% | 137.72% | 170.06% | 1,023.53% |
| Earnings from Continuing Operations | -255.27% | -196.64% | -183.89% | -81.84% | -80.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -557.32% | -19.78% | 104.88% | 112.78% | 95.70% |
| Net Income | 57.23% | -566.69% | -751.27% | -456.02% | -191.03% |
| EBIT | -56.72% | -28.20% | -30.81% | -46.38% | 30.21% |
| EBITDA | -57.82% | -34.25% | -32.70% | -42.93% | 26.89% |
| EPS Basic | 54.59% | -565.38% | -740.38% | -451.43% | -168.13% |
| Normalized Basic EPS | -350.00% | -395.45% | -218.75% | 170.00% | -82.43% |
| EPS Diluted | 54.59% | -565.38% | -740.38% | -451.43% | -168.13% |
| Normalized Diluted EPS | -350.00% | -395.45% | -218.75% | 170.00% | -82.43% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.01% | 0.01% | 8.86% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.01% | 0.01% | 8.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |